Singapore: BRIM Biotechnology has collaborated with Janssen Pharmaceutica to pursue research, development and commercialization of certain compounds identified by Janssen that are targeted for dengue indications.

BRIM (Beyond Research and Innovative Medicines) is a preclinical/clinical development company focused on using translational sciences to develop affordable and high quality medicines, began operating in August 2013 and is based in Taipei, Taiwan.

Dr Haishan Jang, president and CEO, BRIM stated, "We are extremely excited and enthusiastic about working with Janssen in developing effective treatment for dengue. There is a high unmet medical need in dengue, especially in Asia. With Janssen's experienced Infectious Diseases team and BRIM's core competencies in translational sciences and integrated operation management in Asia, we are confident at progressing the compounds toward a high quality affordable drug candidate for Dengue disease."

Dengue is ranked by WHO as the most important mosquito-borne viral disease, with approximately 2.5 billion people live in dengue endemic countries, and is seeing rapid and ongoing expansion related to increasing global spread of the viral vector.